文献速递胸部肿瘤支持与姑息治疗

肺癌患者的COVID-19特征与严重性决定因素

COVID-19 in patients with lung cancer.
PubMed 文献 · Ann Oncol · 2020-06-17

单中心研究纳入102例肺癌合并COVID-19患者,发现62%住院、25%死亡,严重性主要由患者特异性因素(吸烟状态、COPD)决定,而非癌症特异性因素或近期治疗;HLA超型在轻重症间无显著差异,羟氯喹未改善住院患者结局。

要点

  • 肺癌合并COVID-19患者住院率62%、死亡率25%。
  • 吸烟状态和COPD是重症独立决定因素,近期手术或系统治疗不影响严重性。
  • 多数患者康复,包括25%初始需插管的患者;羟氯喹未见获益。

核心结论

  • COVID-19在肺癌患者中导致高疾病负担,但患者特异性因素而非癌症特异性因素或治疗是严重性的最大决定因素。

研究设计与样本

  • 单中心连续纳入2020年3月12日至5月6日确诊COVID-19的肺癌患者102例,预设严重性阈值包括住院、ICU/插管/不插管复合指标或死亡。

主要发现

  • 62%患者住院,25%死亡,COVID-19占疫情期间肺癌总死亡的11%。
  • 严重COVID-19的比值比:吸烟中位23.5包年对比从不吸烟者为2.9(95%CI 1.07-9.44),COPD为3.87(95%CI 1.35-9.68)。
  • 既往胸部手术/放疗和近期系统治疗未影响COVID-19严重性。
  • HLA超型在轻症或重症COVID-19与非COVID-19肺癌对照间总体相似。
  • 多数患者康复,包括25%初始需插管的患者;住院患者中羟氯喹未改善COVID-19结局。

临床怎么用

  • 对肺癌患者应重视吸烟状态和COPD等患者特异性因素以评估COVID-19重症风险。
  • 近期胸部手术/放疗或系统治疗不应因COVID-19风险而常规延迟。
  • 羟氯喹不推荐用于改善肺癌合并COVID-19住院患者的结局。

局限性

  • 单中心回顾性设计,样本量有限(n=102),HLA分析仅46例。
  • 未报告多变量模型细节及混杂因素调整情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with lung cancers may have disproportionately severe coronavirus disease 2019 (COVID-19) outcomes. Understanding the patient-specific and cancer-specific features that impact the severity of COVID-19 may inform optimal cancer care during this pandemic. PATIENTS AND METHODS: We examined consecutive patients with lung cancer and confirmed diagnosis of COVID-19 (n = 102) at a single center from 12 March 2020 to 6 May 2020. Thresholds of severity were defined a priori as hospitalization, intensive care unit/intubation/do not intubate ([ICU/intubation/DNI] a composite metric of severe disease), or death. Recovery was defined as >14 days from COVID-19 test and >3 days since symptom resolution. Human leukocyte antigen (HLA) alleles were inferred from MSK-IMPACT (n = 46) and compared with controls with lung cancer and no known non-COVID-19 (n = 5166). RESULTS: COVID-19 was severe in patients with lung cancer (62% hospitalized, 25% died). Although severe, COVID-19 accounted for a minority of overall lung cancer deaths during the pandemic (11% overall). Determinants of COVID-19 severity were largely patient-specific features, including smoking status and chronic obstructive pulmonary disease [odds ratio for severe COVID-19 2.9, 95% confidence interval 1.07-9.44 comparing the median (23.5 pack-years) to never-smoker and 3.87, 95% confidence interval 1.35-9.68, respectively]. Cancer-specific features, including prior thoracic surgery/radiation and recent systemic therapies did not impact severity. Human leukocyte antigen supertypes were generally similar in mild or severe cases of COVID-19 compared with non-COVID-19 controls. Most patients recovered from COVID-19, including 25% patients initially requiring intubation. Among hospitalized patients, hydroxychloroquine did not improve COVID-19 outcomes. CONCLUSION: COVID-19 is associated with high burden of severity in patients with lung cancer. Patient-specific features, rather than cancer-specific features or treatments, are the greatest determinants of severity.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Luo J, Rizvi H, Preeshagul IR, et al. COVID-19 in patients with lung cancer. Ann Oncol. 2020. PMID: 32561401. doi:10.1016/j.annonc.2020.06.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。